Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent
March 01, 2017 08:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 01, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program
February 27, 2017 08:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
February 16, 2017 07:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent
January 05, 2017 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
Clearside Biomedical, Inc. to Present at J.P. Morgan Healthcare Conference
January 05, 2017 07:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer
January 04, 2017 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index
December 14, 2016 16:15 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
December 09, 2016 09:20 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
December 07, 2016 16:02 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema
November 15, 2016 08:23 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...